


RESEARCH ARTICLE

Open Access





Shinichiro Kashiwagi^{*}, Naoyoshi Onoda, Yuka Asano, Kento Kurata, Tamami Morisaki, Satoru Noda, Hidemi Kawajiri, Tsutomu Takashima and Kosei Hirakawa

Abstract

Background: Breast-preserving surgery (Bp) and sentinel lymph node biopsy (SNB) are established as standard treatment for axillary lymph node-negative early breast cancer.

Methods: A surgical technique using manual blunt dissection (MBD), in which use of electrocautery, an ultrasonically activated scalpel, and ligation is minimized, is described. This involves an approach from small incisions in the axilla or areola to avoid injury to skin flaps, and with adequate mobilization of the breast, so that regardless of the tumor site, surgical wounds are not noticeable. The usefulness and tolerability of this surgical technique were examined.

Results: This surgical technique was evaluated in 233 patients. Surgery could be performed rapidly, with a mean operative time of 67 ± 21 min and a low mean blood loss of only 35 ± 28 ml. There was little need for postoperative analgesia, and surgery was well tolerated without postoperative bleeding or wound infection.

Conclusion: Our proposed technique for partial mastectomy using MBD provides good curative and cosmetic results

Keywords: Breast cancer, Manual blunt dissection, Partial mastectomy, Surgery, Breast-preserving surgery

Background

Breast-preserving surgery (Bp) and sentinel lymph node biopsy (SNB) are established as standard treatment for axillary lymph node-negative early breast cancer [1–3]. With the addition of appropriate postoperative radiotherapy, survival rates equivalent to mastectomy, low recurrence in the preserved breast, and acceptable treatment outcomes have been achieved [4–6]. New surgical techniques to maintain these cure rates and provide good cosmetic results must now be developed.

A surgical technique using manual blunt dissection (MBD), in which use of electro cautery, an ultrasonically activated scalpel, and ligation is minimized, is described. It involves an approach from small incisions in the axilla or areola to avoid injury to skin flaps, and with adequate mobilization of the breast, so that regardless of the tumor site, surgical wounds are not noticeable. The

usefulness and tolerability of this surgical technique were examined.

Methods

Patient characteristics

This study included patients with primary breast cancer that was confirmed preoperatively by needle biopsy between January 2010 and December 2012. Surgical outcomes for 233 patients who underwent Bp + SNB at our hospital are shown. The indications for this surgery were a preoperative diagnosis of ductal carcinoma in situ (DCIS) or tumor size ≤3 cm for invasive carcinoma, each without clinical axillary node metastases (cN0) [2]. Lesion extent was assessed by ultrasound and magnetic resonance imaging (MRI). For the mammary excision stump, a tumor margin that was less than 5 mm was considered positive and, in positive cases, a radiation boost of 10 Grays was added. In addition, when there was marked denudation of the cancer nest, re-excision was performed. Cosmesis was evaluated after Bp using a patient-based tool, the "Four points of evaluation of Harvard" [7].

^{*} Correspondence: spqv9ke9@view.ocn.ne.jp Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan



© 2015 Kashiwagi et al. **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Axillary clearance was indicated for SN metastasis, defined as macrometastasis (i.e., tumor diameter >2 mm) in the SN. The presence of micrometastasis (i.e., tumor diameter >0.2 mm, ≤2 mm, or <200 tumor cells) or isolated tumor cells (ITCs, i.e., tumor diameter <0.2 mm or <200 tumor cells) was not considered an indication for axillary clearance [8].

This study was performed in accordance with the Declaration of Helsinki and carried out with the approval of the Ethical Review Board of Osaka City University (#926). A sufficient explanation was provided, and written, informed consent was obtained from all study subjects for their involvement in this study and for the storage and use of their data.

Surgical procedure

The target tumor was confirmed by palpation and ultrasound before surgery (solid line), and markings were made at 1-cm margins on the skin directly above (dotted line) the planned resection site (Fig. 1a). Lidocaine jelly mixed with indigo carmine was percutaneously injected along the markings (dotted line) into the breast surface of the mammary gland (Fig. 1b), and about 40 mL of 1 % lidocaine + epinephrine (3-fold dilution) were injected subcutaneously around the planned area of dissection for the purpose of hemostasis.

First, a 2-cm skin incision was made into the axilla for SNB, and the sentinel lymph node (SN) was sent fresh for intraoperative histopathology (Fig. 1c). The SN was identified using radioisotope (RI) and staining methods [9–13]. For the RI method, 1 millicurie (mCi)/mL of

99 m-technetium (Tc)-phytate colloid was injected intradermally and subcutaneously directly above the tumor and around the tumor on the day before surgery [14-16]. Lymphoscintigraphy was then performed to identify a possible SN outside the axilla and search for the SN during surgery. For the staining method, 5.0 mL of indocyanine green (Diagnogreen; Daiichi Sankyo, Tokyo, Japan) were injected subcutaneously to make a wheal in the areola of the affected breast [17]. The area around the injection was lightly massaged, and about 10 min later, a skin incision was made to identify a green-stained lymph node as the SN. The SN was removed, cut into 2-mmthick sections, and histopathologically examined by an experienced pathologist. Only macrometastases were considered positive, whereas micrometastases and ITCs were considered negative [8, 18, 19]. Patients with a positive SN underwent further axillary lymph node dissection [20].

Next, a skin incision was made in the areola to perform a partial mastectomy (Fig. 1d). A crescent-like incision was made to expose the surgical field (an arc-like incision was made in the breast margin for the tumor in the outer upper region, and SNB + Bp were performed from the same surgical wound). The skin around the wound margin was grasped with sharp towel clamps, and a 1 to 2-mm length of skin and subcutaneous fat was dissected by electro cautery (Fig. 2a). Blunt subcutaneous dissection was performed using curved Cooper scissors. The Cooper scissors were held with the tip toward the skin side, and, with the tip closed, the tip was slid along the back of the skin and pushed (Fig. 2b). Dissection of the planned area, including directly above the




Fig. 1 Surgical procedure of MBD (I). The target tumor was confirmed by palpation and ultrasound before surgery (a). Lidocaine jelly mixed with indigo carmine was percutaneously injected (b). A 2-cm skin incision was made into the axilla for SNB (c). A skin incision was made in the areola to perform a partial mastectomy (d)




Fig. 2 Surgical procedure of MBD (II). The skin around the wound margin was grasped with sharp towel clamps (**a**). Blunt subcutaneous dissection was performed using curved Cooper scissors (**b**). Using counter traction with the towel clamps, the subcutaneous tissue was dissected (**c**). The breast in the planned area of dissection was completely mobilized from the skin (**d**)

tumor, proceeded in various directions. Using counter traction with the towel clamps, the subcutaneous tissue was dissected, being careful to avoid pulling of the breast skin (Fig. 2c). With the procedure thus far, only Cooper's ligament remained, so Cooper's ligament was manually dissected, and the breast in the planned area of dissection was completely mobilized from the skin (Fig. 2d).

The breast was incised vertically along the markings near the areola until the retromammary space was reached, and then the retromammary space was manually dissected. This area was widely dissected to facilitate breast flap mobilization after resection. While removing the breast tissue through the surgical wound, dissection proceeded along the markings for breast tumor resection (Fig. 3a). Retention sutures were attached to the resected




Fig. 3 Surgical procedure of MBD (III). Removing the breast tissue through the surgical wound (**a**). The resected tumor specimen was confirmed, retention sutures were placed on the nipple side (**b**), and the breast margins were sutured and closed (**c**). The wound was closed with buried subcuticular sutures (**d**)

tumor specimen so that the pathologists could understand which was the nipple side at the time of pathological diagnosis (Fig. 3b), and the breast margins were sutured and closed (Fig. 3c). If any skin was being pulled during suture closure, further subcutaneous dissection in this area was performed to avoid pulling. The wound was closed with buried subcuticular sutures and cyanoacrylate adhesive applied to the skin. In principle, no drains were placed (Fig. 3d).

Results

This surgical technique was evaluated in 233 patients. Surgery could be rapidly performed, with a mean operative time of 67 (range 42-126, median 68, standard deviation 21) min and a low mean blood loss of only 35 (range 1-136, median 33, standard deviation 28) ml. Breast reconstruction by lateral tissue flap (LTF) was done in 18 cases (7.7 %). Re-excision was performed in five cases (2.1 %) to save tumor stump exposure. Macrometastasis was detected in 31 patients (13.3 %), and all of these patients underwent axillary lymph node dissection. Micrometastasis was observed in 20 patients (8.6 %). Cosmesis was evaluated as "Good" or better by 198 cases (85.0 %) (Excellent n = 86, Good n = 112, Fair n = 29, Poor n = 6). There was little need for postoperative analgesia, and surgery was well tolerated, with little postoperative bleeding or wound infection (hematoma n = 3, wound infection n = 1) (Table 1).

Discussion

Bp is minimally invasive and now considered standard treatment for early breast cancer [1–3]. However, with a partial mastectomy for tumor resection, some degree of breast deformity is difficult to avoid, and patients may be concerned about surgical scars of the breast skin. We use an incision of the anterior axillary line or areola to preserve skin directly above the tumor. In addition, for any deformity due to breast resection, breast reconstruction using residual breast and adipose tissue, or simultaneous breast reconstruction using an autologous LTF or latissimus dorsi muscle flap (LDMF) can

be performed. This has provided excellent cosmetic results [21, 22]. The results of the present study apply to the small breasts of Japanese women, but, in the case of larger breast patients or patients with ptosis, MBD may be difficult when considering the distance from the skin incision to the tumor.

Electrocautery and thermal cautery were previously used for flap creation, but this often caused flap skin damage or burn. However, MBD using Cooper scissors can be used to quickly create a wide flap without skin damage and thus reduce operative time. With wide flap creation and adequate dissection of the retromammary space, an axillary or areolar approach can be used for an inconspicuous surgical scar, regardless of the tumor site. Our surgical technique enables breast flap reconstruction without skin pulling to provide excellent cosmetic results. In the present study, general anesthesia was used, but MBD is thought to be possible under local anesthesia [23].

Postoperative bleeding due to blunt dissection may be a concern, but with adequate infiltration of 1 % lidocaine + epinephrine (3-fold dilution), little postoperative bleeding was noted with mild postoperative compression with absorbent gauze.

Dissemination of cancer cells by tearing the tumor may be considered when applying blunt dissection, so our surgical technique is not indicated in patients with suspected tumor infiltration into the skin. However, because a subcutaneous skin flap with appropriate layers can be created with minimal sharp dissection, there is little or no risk of cutting into the tumor. Surgeons at our institution have been performing this surgical procedure since 2004, and no local recurrence due to our dissection technique has occurred. Long-term evaluation in a larger number of cases, however, would be desirable.

Conclusions

In conclusion, our proposed technique for partial mastectomy using MBD provides good curative and cosmetic results.

Table 1 Patient background and operation outcomes

Parameters	Bp + SNB (n = 233)
Age (years)	mean 59 (range 30–95, median 59, standard deviation 13)
Tumor diameter (cm)	mean 2.0 (range 0.4–3.8, median 2.0, standard deviation 0.8)
Operation time (min)	mean 67 (range 42–126, median 68, standard deviation 21)
Estimated blood loss (ml)	mean 35 (range 1–136, median 33, standard deviation28)
Frequency of total analgesics	mean 2.5
Cosmesis (Four points of evaluations of Harvard)	Excellent 86, Good 112, Fair 29, Poor 6
Postoperative bleeding	3
Wound infection	1

 \emph{Bp} breast-preserving surgery, \emph{SNB} sentinel lymph nodes biopsy

Abbreviations

Bp: Breast-preserving surgery; SNB: Sentinel lymph node biopsy; MBD: Manual blunt dissection; MRI: Magnetic resonance imaging; DCIS: Ductal carcinoma in situ; SN: Sentinel lymph node; RI: Radioisotope; LTF: Lateral tissue flap; LDMF: Latissimus dorsi muscle flap..

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors were involved in the preparation of this manuscript. SK participated in the design of the study and drafted the manuscript. NO helped with data collection and manuscript preparation. YA, KK, TM, and SN helped with study data collection and participated in its design. HK and TT helped with data collection and manuscript preparation. SK and KH conceived the study, and participated in its design and coordination and helped to draft the manuscript. All authors have read and approved the final manuscript.

Acknowledgments

The authors would like to thank Sae Ishihara and Mao Tokumoto (Department of Surgical Oncology, Osaka City University Graduate School of Medicine) for helpful advice.

Received: 29 April 2015 Accepted: 12 October 2015 Published online: 22 October 2015

References

- Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.
- Saji S, Hiraoka M, Tokuda Y, Fukui N, Ikeda T. Trends in local therapy application for early breast cancer patients in the Japanese Breast Cancer Society Breast Cancer Registry during 2004–2009. Breast Cancer. 2012;19(1):1–3.
- Jakub JW, Pendas S, Reintgen DS. Current status of sentinel lymph node mapping and biopsy: facts and controversies. Oncologist. 2003;8(1):59–68.
- Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347(16):1233–41.
- Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. NEngl J Med. 2002; 347(16):1227–32.
- Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, et al. Eighteen-year results inthe treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 2003; 98(4):697–702.
- Harris JR, Levene MB, Svensson G, Hellman S. Analysi of cosmetic results following primary radiation therapy for stage I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1983;52:442–5.
- Houvenaeghel G, Nos C, Mignotte H, Classe JM, Giard S, Rouanet P, Lorca FP, Jacquemier J, Bardou VJ. Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer: Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement–Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer. J Clin Oncol. 2006;24:1814-22.
- Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsyand lymphatic mapping of patients with breast cancer. Ann Surg. 1998;227(5):645-653.
- Noguchi M, Motomura K, Imoto S, Miyauchi M, Sato K, Iwata H, et al. A
 multicenter validation study of sentinel lymph node biopsy by the Japanese
 Breast Cancer Society. Breast Cancer Res Treat. 2000;63(1):31–40.
- Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996: 276(22):1818–22.
- 12. McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to

- routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000; 18(13):2560–2566.
- Cody HS, 3rd, Fey J, Akhurst T, Fazzari M, Mazumdar M, Yeung H, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol. 2001; 8(1):13–19.
- Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al: The sentinel node in breast cancer–a multicenter validation study. N Engl J Med. 1998: 339(14):941-46.
- Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.
 N Engl J Med. 2003; 349(6):546–53.
- Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoidaxillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997; 349(9069):1864-67.
- Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15(6):2345–50.
- Turner RR, Chu KU, Qi K, Botnick LE, Hansen NM, Glass EC, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000; 89(3):574–81.
- Cserni G, Gregori D, Merletti F, Sapino A, Mano MP, Ponti A, et al. Metaanalysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg. 2004; 91(10):1245–52.
- Lyman GH, Giuliano AE, Somerfield MR, Benson AB, 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005; 23(30):7703–20.
- 21. Ohuchi N, Harada Y, Ishida T, Kiyohara H, Satomi S. Breast-coserving surgery for primary breast cancer: immediate volume replacement using lateral tissue flap. Breast Cancer. 1997;4(3):135–41.
- 22. Takeda M, Ishida T, Ohnuki K, Suzuki A, Kiyohara H, Moriya T, et al. Breast conserving surgery with primary volume replacement using a lateral tissue flap. Breast Cancer. 2005; 12(1):16-20.
- Kashiwagi S, Onoda N, Takashima T, Asano Y, Aomatsu N, Nakamura N, et al. Breast Conserving Surgery and Sentinel Lymph Node Biopsy under Local Anesthesia for Breast Cancer. J Cancer Ther. 2012; 3:810–813.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH ("Springer Nature").

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users ("Users"), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use ("Terms"). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

- 1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control:
- 2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful:
- 3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
- 4. use bots or other automated methods to access the content or redirect messages
- 5. override any security feature or exclusionary protocol; or
- 6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com